What Is
Idiopathic Pulmonary Fibrosis?

The interstitial lung diseases, or ILDs, are a group of over 200 conditions that may result in lung inflammation and scarring. In the most severe form, this leads to Pulmonary Fibrosis (PF) a chronic condition characterised by shortness of breath.

In many cases, we can determine the disease or injury that caused PF, for example, exposure to feathers and dusts and some drugs may cause hypersensitivity pneumonitis and PF (see ILD section).  However, the most common and severe form of PF has no known cause and is called Idiopathic PF, or IPF.  IPF is a distinct disease that usually affects older patients. Although there are over 200 related ILDs, IPF is the most common.

‘Idiopathic’ means unknown and hence the cause of Idiopathic Pulmonary Fibrosis (IPF) is unknown. In some patients, the disease is genetic. Environmental factors (particularly exposure to certain types of dusts) may also play a role. What is known is that Pulmonary Fibrosis changes the lung’s ability to function normally. Typically, mild scarring of the lung tissue occurs first, but, over months and years, the normal lung tissue is replaced by more heavily scarred lung tissue, which makes it difficult to breathe and deliver needed oxygen to the body.

Even though the cause of IPF is still being investigated, the following are considered to be risk factors for disease development:

  • Viral Infections.
  • Exposure to dust / fumes and smoking.
  • Age /gender (diagnosis is more common in men and older people).
  • Acid reflux from the stomach into the lungs.
    IPF affects each person differently and the disease progresses at varying rates. For some, the scarring occurs quickly, while in others, it happens over a longer period of time. Symptoms also vary from moderate to severe and may stay the same for a while.

At this point, there is no cure for IPF, which is why Breathing Matters is supporting UCL Respiratory research.

The treatment options are limited since scarring appears to be permanent once it has developed. Lung transplantation is one of the few options available. There are two therapies that are approved by National Institute of Clinical Excellent (NICE) and are available for NHS-England patients with moderately severe IPF as assessed by lung function.  Both drugs are similarly effective in reducing the rate at which the lungs scar. However, the side effects of either treatment can be limiting and a lung specialist is required to determine what treatment is appropriate.

Further information on the drugs available to treat IPF can be found here

Pulmonary fibrosis causes decreased oxygen levels in the blood which can lead to a condition known as pulmonary hypertension, and patients with pulmonary fibrosis are frequently treated with supplemental oxygen to prevent heart failure.

In addition to the medicines, there are also non-drug approaches available that can help manage pulmonary fibrosis symptoms. Pulmonary rehabilitation, often combined with oxygen therapy, may help improve the ability to function without severe breathlessness.

Pulmonary rehabilitation involves nutritional advice, exercise and breathing techniques, whilst oxygen therapy allows the patient to continue being as active as possible.

Living With Pulmonary Fibrosis

Please consult your doctor before making changes to your lifestyle.

  • Quit smoking to help increase oxygen levels in your blood and lower blood pressure and heart rate.
  • Eat less saturated fat and more fruits and vegetables.
  • Exercise to help keep your body working as efficiently as possible.
  • Lose excess weight to help improve your breathing capacity.
  • Avoid situations in which you might catch infections from others.
  • Avoid excessive pollutants and dust.
  • Try to stay mentally active.
  • Seek emotional support through family, friends, healthcare providers and support groups.
  • Don’t over-exert yourself and ensure you get enough rest.
  • Make sure your immunisations are up to date.

Ongoing Research

Our fantastic research team at the Centre for Inflammation and Tissue Repair (CITR) at UCL Respiratory aims to find better ways to diagnose, treat, and ultimately find a cure for pulmonary fibrosis. The research is both clinical, involving patients, and laboratory based.

The current clinical trials we are involved in includes:

  • Investigation of matrix regulation in chronic lung disease: Chronic respiratory disease is characterised by lung scarring or fibrosis. This work investigates the development of scar tissue in disease as diverse as pulmonary fibrosis, asthma and tuberculosis. By understanding the mechanisms that underlie the scarring process, we can help to develop drugs to overcome it.
  • Autoantibodies and pulmonary fibrosis: Studying the role of auto-antibodies (antibodies that the body makes against its own organs) in pulmonary fibrosis. In particular, we are developing ways to looking for auto-antibodies that attack patients’ own blood vessels in patients with interstitial lung diseases including IPF and rheumatoid arthritis associated ILD.
  • Molecular imaging studies to investigate mechanisms, prognosis and response to therapy in interstitial lung disease: Investigating the ability of special scans, called PET scans, to light up active areas of lung fibrosis to help us decide on treatment courses.
  • Circulating white blood cells:  We have shown that a specific type of circulating white blood cells, called neutrophils, are different in patients with IPF and can help us predict which patients will do less well than others. We are trying to find out more about why this happens and whether the abnormal neutrophils are the result of, or the cause of, the lung disease. 
  • Activation of white blood cells in the lung: We have shown that white blood cells are activated in the lungs of patients with pulmonary fibrosis and are carrying out studies to find out what causes this activation and whether it can be reversed. In particular, we are investigating the effect of low oxygen concentration on white cell activation in IPF and other diseases.
  • Airway epithelial project: We are able to look at the interactions of white cells and the lung epithelium and compare the white cells from patients with pulmonary fibrosis to those from control patients with no lung disease. We are particularly interested in how the mucin Muc5B (that gives sputum it’s ‘stringy’ quality might influence these interactions.  We are also looking at whether genetic material from the lung can be detected in blood of patients with IPF allowing a test for earlier diagnosis, and to measure response to novel treatments.
  • Platelets and pulmonary fibrosis: Investigating the role of platelets in IPF and other ILDs. We have studies looking at whether platelets accumulate in the lungs of patients with lung fibrosis, and whether platelets are abnormally ‘sticky’ in these patients. Our results are hopefully going to be published later this year.
  • The anticoagulation in IPF study: For many years, it has been recognised that patients with IPF are at increased risk of blood clots. We are looking at whether patients derive benefits from taking drugs that ‘thin’ the blood to prevent clots.  We are completing a study this year and hope to publish the results and apply for a bigger study.
  • The INHALE study: Investigating whether new drugs for pulmonary fibrosis can be delivered directly to the lungs via inhalation and therefore avoiding toxic side-effects.  This study has been submitted for publication.
  • Novel imaging: We are looking at machines learning to teach computers to read CT scans in lung diseases, such as IPF and sarcoid. This will allow us to be more accurate in comparing scans between patients and in the same patient, over time or with treatment.
  • Novel treatments: In collaboration with industry, we are taking part in three studies of novel agents in IPF, and one novel way of measuring response to treatment in sarcoidosis.
  • Post-COVID-19: we are carrying out studies looking at the development of ILD in patients with COVID-19. This is a rare side-effect of COVID-19 affecting around 4-6% of patients, but may give us valuable insights into the development of ILD.

Breathing Matters Impact Report 2021

See how your donations have contributed to our groundbreaking research

2021 Impact Report

Sign Up!

Receive our latest research updates and news

  • This form collects your name and email address so that we can keep you updated with news and information about Breathing Matters. Please check our Privacy Policy to see how we protect and manage your data.

Sign up to receive our news and updates

  • This form collects your name and email address so that we can keep you updated with news and information about Breathing Matters. Please check our Privacy Policy to see how we protect and manage your data.

Where there's research there's hope

Research into respiratory conditions accounts for just 2% of all the medical research funding in the UK.

Will you support respiratory research?